Menactra protects despite error.(Clinical Capsules)(Drug overview)(Brief article)

Pediatric News,  November, 2006  by Splete, Heidi

• E-mail
• Print
• Link

Persons who mistakenly received the meningococcal conjugate vaccine (Menactra) subcutaneously rather than intramuscularly were nonetheless sufficiently protected, according to a report by the Centers for Disease Control and Prevention.

The CDC received reports that 101 persons aged 11-47 years (median age 17.5 years) in seven states received the new meningococcal vaccine (MCV4) subcutaneously, although it is licensed for intramuscular use only. Of these, 38 agreed to participate in an investigation to show whether revaccination was needed (MMWR 2006;55:1016-7).

Overall, 36 of ...

Read the rest of this article with a Free Trial at HighBeam Research.